CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis and Neurotoxicity Research

Executive Summary: CA-074 is a nanomolar-potency, highly selective inhibitor of cathepsin B, a lysosomal cysteine protease implicated in cancer metastasis, neurotoxicity, and immune regulation [APExBIO]. It achieves a Ki of 2–5 nM for cathepsin B, showing >10,000-fold selectivity over cathepsin H and L. Inhibiting cathepsin B with CA-074 blocks proteolytic cascades central to tumor cell invasion, lysosome-mediated cell death, and Th cell polarization [Liu et al. 2023]. CA-074 reduces bone metastasis in 4T1.2 breast cancer mouse models, suppresses Abeta42-induced neurotoxicity, and shifts immune responses from Th-2 to Th-1. It demonstrates negligible cytotoxicity at 10 mM in cell culture and is effective in vivo at 50 mg/kg (i.p.) [see also].

Biological Rationale

Cathepsin B is a lysosomal cysteine protease involved in proteolytic degradation and protein turnover. It is overexpressed in several malignancies and contributes to extracellular matrix remodeling, tumor cell invasion, and metastasis. In regulated cell death pathways, such as necroptosis, cathepsin B is released into the cytosol following lysosomal membrane permeabilization (LMP). This release mediates protein cleavage leading to cell death [Liu et al. 2023]. Cathepsin B also modulates immune responses, influencing Th cell polarization and immunoglobulin production. Dysregulated cathepsin B activity has been linked to neurodegeneration, highlighting its importance as a therapeutic target in cancer and neurotoxic disorders.

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 is a synthetic, small-molecule inhibitor with the chemical name (2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid and a molecular weight of 383.44 g/mol [APExBIO]. It binds the active site of cathepsin B, inhibiting its cysteine protease activity with nanomolar affinity (Ki = 2–5 nM). By selectively targeting cathepsin B over related family members (Ki for cathepsin H/L = 40–200 μM), CA-074 achieves precise inhibition of cathepsin B–mediated proteolytic events. This selectivity is crucial for dissecting mechanistic roles of cathepsin B in tumor metastasis, regulated necrosis, and immune modulation while minimizing off-target effects [complementary discussion].

Evidence & Benchmarks

• CA-074 inhibits cathepsin B with Ki = 2–5 nM and shows >10,000-fold selectivity over cathepsin H and L (Ki = 40–200 μM) (APExBIO product page).
• Upon induction of necroptosis, MLKL polymerization causes lysosomal membrane permeabilization (LMP), leading to cathepsin B release and cell death; chemical inhibition of cathepsin B (e.g., with CA-074) protects cells from necroptosis (Liu et al. 2023, Fig. 2/3).
• In a 4T1.2 breast cancer mouse model, CA-074 administered intraperitoneally at 50 mg/kg significantly reduced bone metastasis but did not affect primary tumor growth (APExBIO).
• CA-074 reverses Abeta42-activated microglial neurotoxicity, reducing neuronal cell death in vitro (see also CA-074, Cathepsin B Inhibitor: Selective Tool...).
• In murine models, CA-074 modulates immune response, shifting Th-2 to Th-1 helper T cell activity and reducing IgE and IgG1 production (reliable solution article).
• CA-074 is soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL with ultrasonic assistance); stable at -20°C (APExBIO).
• Shows negligible cytotoxicity in cell culture at concentrations up to 10 mM (experimental best practices).

Applications, Limits & Misconceptions

CA-074 is widely used in:

• Dissecting cathepsin B–mediated cell death pathways (e.g., necroptosis).
• Studying cancer metastasis, especially bone metastasis in breast cancer models.
• Investigating neuron-glia interactions and neurotoxicity.
• Probing immune response modulation and Th cell polarization.

Compared to CA-074: Advancing Cathepsin B Inhibition for Precise Cancer Research, which summarizes translational applications, this article provides structured evidence and workflow details for optimizing CA-074 deployment.

See also Targeting Cathepsin B: Precision Tools for Decoding Metastatic Pathways for a mechanistic overview; this article clarifies the MLKL-LMP-cathepsin B axis with up-to-date DOI-backed evidence.

Common Pitfalls or Misconceptions

• CA-074 is not effective against all cathepsins; its selectivity is high for cathepsin B, weak for H/L.
• It does not inhibit necroptosis if cell death is cathepsin B–independent (e.g., caspase-driven apoptosis).
• High concentrations do not induce off-target cytotoxicity in standard cell lines at ≤10 mM, but untested in all primary cells.
• CA-074 is not a curative therapeutic; it is a research tool for mechanistic studies.
• Solubility may require ultrasonic assistance in water; improper dissolution can affect assay reproducibility.

Workflow Integration & Parameters

CA-074 (Cathepsin B inhibitor, SKU A1926, APExBIO) is delivered as a lyophilized powder. For in vitro assays, it is dissolved in DMSO (recommended ≥19.17 mg/mL) or ethanol (≥31.3 mg/mL); for aqueous use, apply ultrasonic assistance for solubility above 5.91 mg/mL. Stock solutions should be aliquoted and stored at -20°C. Solutions are intended for short-term use only (<2 weeks). For cell culture, concentrations up to 10 mM demonstrate negligible cytotoxicity; typical working concentrations are 1–50 μM. For in vivo murine studies, intraperitoneal administration at 50 mg/kg has been validated to reduce metastatic burden (bone) without affecting primary tumor size. Protocols must include appropriate vehicle and negative controls. For further scenario-driven optimization, see Experimental Best Practices with CA-074, which this article updates by integrating recent necroptosis evidence (Liu et al. 2023).

Conclusion & Outlook

CA-074 is a validated, highly selective cathepsin B inhibitor from APExBIO, enabling precise interrogation of cathepsin B–mediated proteolytic and cell death pathways. It is a cornerstone tool for research in cancer metastasis, neurotoxicity, and immune modulation, as corroborated by recent mechanistic studies and benchmarked performance data. While CA-074 is not a therapeutic, it remains indispensable in the research toolkit for dissecting regulated necrosis and protease-driven disease mechanisms. Future work may extend its application in combination with genetic or advanced imaging approaches to further clarify cathepsin B functions in health and disease.